Cardiol Therapeutics adds OSC-requested disclosure to US$150 million shelf prospectus filing
CRDL•Expanded disclosure added
The filing adds expanded R&D program timelines and cost disclosure, G&A expense breakdowns, and updated use-of-proceeds reporting for an October 2024 financing.
Additional contracts to be filed
Additional material contracts will be filed alongside the prospectus, including supplier and development agreements.
Shelf prospectus filed after OSC staff review
Cardiol Therapeutics filed a preliminary short form base shelf prospectus following an Ontario Securities Commission staff review.
No restatement of financial statements reported
Management reported no restatement or amendment to previously filed financial statements, expenses, cash flows, or cash position.
